First patient dosed in Ph 1 KOALA trial of KMCAR™ T-cell therapy in patients with R/R kappa-restricted multiple myeloma
Dr Rosanne Dunn, Chief Scientific Officer at HaemaLogiX, said: “We are delighted with the encouraging results from the first safely treated patient, and very pleased to be moving forward to dosing the second patient at a higher dose of KMCAR™ T-cell therapy. Multiple myeloma is the world’s second-most common blood cancer, and there is a significant need for therapies that do not cause immunodeficiency which may result in life threatening infections. Seeing this work translate from the laboratory into human trials with positive safety data is a very important step forward for our immunotherapy programs. Our thanks to the first patient for joining the study and to our colleagues at Peter MacCallum Centre of Excellence for Cellular Immunotherapy for their commitment to progressing this important study.”
Share:
More News
Dr Jing He, Head of R&D China, AstraZeneca, said: “These positive data underscore the pivotal role of ORPATHYS® in intercepting MET-driven resistance early in the treatment journey. By combining the targeted precision of ORPATHYS® with backbone TAGRISSO®, SANOVO demonstrates a meaningful clinical advancement for treatment-naïve patients with MET overexpression and
“ADI-212 marks an important milestone in Adicet’s strategy to address the complexity of solid tumors and represents an important addition to our portfolio of allogeneic gamma delta 1 cell therapies and in vivo CAR T programs,” said Blake Aftab, Ph.D., Chief Scientific Officer of Adicet Bio. “Designed as a single
“Any decision concerning clinical trials is made with utmost care, keeping patients as our highest priority,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “While this outcome is not what we had envisioned for mRNA as a monotherapy in colorectal cancer, it provides scientific insight into
“These results reinforce our confidence that Ziihera is the new HER2-targeted backbone therapy in first-line HER2+ advanced GEA, replacing trastuzumab and extending survival beyond the current standard of care,” said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals.